论文部分内容阅读
DAF方案治疗原发性肝癌12例,有效率(MR)为5/12(41.67％),稳定率(MR+s)为8/12(66.67％),恶化率为4/12(33.33％)。平均生存期为9个月,中数生存期为5个月。一年生存率为3/12(25.00％)。该方案毒性低,患者可以耐受。
There were 12 cases of primary liver cancer treated with DAF regimen. The effective rate (MR) was 5/12 (41.67%), the stability rate (MR+s) was 8/12 (66.67%), and the exacerbation rate was 4/12 (33.33%). . The average survival period is 9 months, and the median survival period is 5 months. The one-year survival rate is 3/12 (25.00%). The program is low in toxicity and patients can tolerate it.